From the Holderness Family to Grandma C, social media personalities around Raleigh and Durham explain what will get lost if ...

North Carolina-based biotech Tune Therapeutics has raised $175 million in a Series B that will help it to take its lead epigenetic silencing drug, Tune-401, into clinical testing as a potential ...

After hours: January 22 at 6:50:24 PM EST Loading Chart for ACRS ...

Or whatever” Sung to the tune of Victim C’s “Graduation (Friends ... It’s going to reach you.” Durham is home to one of the most shorted stocks. The semiconductor manufacturer Wolfspeed ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

“It’s not an easy life, but it is challenging and rewarding to be a part of this industry.” Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 ...